Cargando…

Atorvastatin for prevention of disease progression and hospitalisation in liver cirrhosis: protocol for a randomised, double-blind, placebo-controlled trial

INTRODUCTION: Patients with liver cirrhosis are often diagnosed late and once complications are present, the 2-year survival is 50%. Increasing evidence supports systemic inflammation and metabolic dysfunction in the hepatic stellate cell as key drivers of progression of cirrhosis. However, there is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kimer, Nina, Grønbæk, Henning, Fred, Rikard Gøran, Hansen, Torben, Deshmukh, Atul Shahaji, Mann, Mathias, Bendtsen, Flemming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Gastroenterology and Hepatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045122/ https://www.ncbi.nlm.nih.gov/pubmed/31980514 http://dx.doi.org/10.1136/bmjopen-2019-035284

Ejemplares similares

Atorvastatin for patients with cirrhosis. A randomized, placebo-controlled trial
por: Kronborg, Thit M., et al.
Publicado: (2023)

Antiviral therapy for prevention of hepatocellular carcinoma in chronic hepatitis C: systematic review and meta-analysis of randomised controlled trials
por: Kimer, Nina, et al.
Publicado: (2012)

PROFIT, a PROspective, randomised placebo controlled feasibility trial of Faecal mIcrobiota Transplantation in cirrhosis: study protocol for a single-blinded trial
por: Woodhouse, Charlotte Alexandra, et al.
Publicado: (2019)

Predictors of response and disease course in patients with inflammatory bowel disease treated with biological therapy—the Danish IBD Biobank Project: protocol for a multicentre prospective cohort study
por: Zhao, Mirabella, et al.
Publicado: (2020)

Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation
por: Monteiro, Sofia, et al.
Publicado: (2021)

Efficacy and tolerance of early administration of tranexamic acid in patients with cirrhosis presenting with acute upper gastrointestinal bleeding: a study protocol for a multicentre, randomised, double-blind, placebo-controlled trial (the EXARHOSE study)
por: Heidet, Matthieu, et al.
Publicado: (2018)

Changing trends of hospitalisation of liver cirrhosis in Beijing, China
por: Bao, Xiao-Yuan, et al.
Publicado: (2015)

Carvedilol for portal hypertension in cirrhosis: systematic review with meta-analysis
por: Li, Tong, et al.
Publicado: (2016)

Economic burden of cirrhosis in Catalonia: a population-based analysis
por: Miquel, Mireia, et al.
Publicado: (2018)

A potential novel inflammation biomarker for predicting the prognosis of decompensated liver cirrhosis
por: Xie, Yanan, et al.
Publicado: (2022)

Neuroimmunomodulation of adrenoblockers during liver cirrhosis: modulation of hepatic stellate cell activity
por: Medina Pizaño, Mariana Yazmin, et al.
Publicado: (2023)

Fibrosis-4 index as a predictor for mortality in hospitalised patients with COVID-19: a retrospective multicentre cohort study
por: Park, Jung Gil, et al.
Publicado: (2020)

Evaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion
por: Weersink, Rianne A, et al.
Publicado: (2016)

Liver cirrhosis in England—an observational study: are we measuring its burden occurrence correctly?
por: Ratib, Sonia, et al.
Publicado: (2017)

Recompensation factors for patients with decompensated cirrhosis: a multicentre retrospective case–control study
por: Xu, Xiaomei, et al.
Publicado: (2021)

A decision tree model to predict liver cirrhosis in hepatocellular carcinoma patients: a retrospective study
por: Zhou, Zheyu, et al.
Publicado: (2023)

Changing epidemiology of cirrhosis from 2010 to 2019: results from the Global Burden Disease study 2019
por: Xiao, Shiyu, et al.
Publicado: (2023)

A practical nomogram based on systemic inflammatory markers for predicting portal vein thrombosis in patients with liver cirrhosis
por: Xing, Yueyi, et al.
Publicado: (2022)

Association between lymphocyte-to-monocyte ratio (LMR) and the mortality of HBV-related liver cirrhosis: a retrospective cohort study
por: Zhang, Jie, et al.
Publicado: (2015)

Timing of endoscopic intervention in patients with cirrhosis with acute variceal haemorrhage (TEACH trial): protocol for a randomised clinical trial (RCT)
por: Yang, Zhuoxin, et al.
Publicado: (2022)

Viusid, a nutritional supplement, increases survival and reduces disease progression in HCV-related decompensated cirrhosis: a randomised and controlled trial
por: Vilar Gomez, Eduardo, et al.
Publicado: (2011)

Antiviral therapy effectively improves liver hemodynamics as evidenced by serum biomarker and contrast-enhanced ultrasound examinations in patients with hepatitis B cirrhosis
por: Xu, Xiaoyong, et al.
Publicado: (2018)

Validation of an algorithm using inpatient electronic health records to determine the presence and severity of cirrhosis in patients with hepatocellular carcinoma in England: an observational study
por: Driver, Robert J, et al.
Publicado: (2019)

Association between medication adherence and disease outcomes in patients with hepatitis B-related cirrhosis: a population-based case–control study
por: Fu, Kuo-Yu, et al.
Publicado: (2022)

RITPBC: B-cell depleting therapy (rituximab) as a treatment for fatigue in primary biliary cirrhosis: study protocol for a randomised controlled trial
por: Jopson, Laura, et al.
Publicado: (2015)

Effectiveness of intravenous albumin therapy to prevent spontaneous bacterial peritonitis, renal dysfunction and death in adults with cirrhosis: a protocol for a systematic review
por: Härmälä, Suvi, et al.
Publicado: (2019)

REpeated AutoLogous Infusions of STem cells In Cirrhosis (REALISTIC): a multicentre, phase II, open-label, randomised controlled trial of repeated autologous infusions of granulocyte colony-stimulating factor (GCSF) mobilised CD133+ bone marrow stem cells in patients with cirrhosis. A study protocol for a randomised controlled trial
por: King, A, et al.
Publicado: (2015)

Direct targeting of risk factors significantly increases the detection of liver cirrhosis in primary care: a cross-sectional diagnostic study utilising transient elastography
por: Harman, David J, et al.
Publicado: (2015)

Nurse-led clinic for patients with liver cirrhosis—effects on health-related quality of life: study protocol of a pragmatic multicentre randomised controlled trial
por: Hjorth, Maria, et al.
Publicado: (2018)

Study protocol: a multicentre, open-label, parallel-group, phase 2, randomised controlled trial of autologous macrophage therapy for liver cirrhosis (MATCH)
por: Brennan, Paul Noel, et al.
Publicado: (2021)

A new model predicts hepatocellular carcinoma in patients with HBV-related decompensated liver cirrhosis and long-term antiviral therapy: a prospective study
por: Mao, Hao-dan, et al.
Publicado: (2023)

Predictive value of liver and spleen stiffness measurement based on two-dimensional shear wave elastography for the portal vein pressure in patients with compensatory viral cirrhosis
por: Wang, Peng, et al.
Publicado: (2023)

FTACMT study protocol: a multicentre, double-blind, randomised, placebo-controlled trial of faecal microbiota transplantation for autism spectrum disorder
por: Chen, Ye, et al.
Publicado: (2022)

Study protocol for a randomised, double-blinded, placebo-controlled, clinical trial of S-ketamine for pain treatment in patients with chronic pancreatitis (RESET trial)
por: Juel, Jacob, et al.
Publicado: (2015)

Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial
por: Buhl, Sine Schnoor, et al.
Publicado: (2014)

Multicentre, randomised, placebo-controlled trial of extract of Japanese herbal medicine Daikenchuto to prevent bowel dysfunction after adult liver transplantation (DKB 14 Study)
por: Kaido, Toshimi, et al.
Publicado: (2015)

Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in Acute Severe Colitis: the IASO trial
por: Thomas, Martin Geoffrey, et al.
Publicado: (2019)

Low-dose naltrexone for the induction of remission in patients with mild to moderate Crohn’s disease: protocol for the randomised, double-blinded, placebo-controlled, multicentre LDN Crohn study
por: Paulides, Emma, et al.
Publicado: (2022)

Protocol for a randomised, placebo-controlled pilot study for assessing feasibility and efficacy of faecal microbiota transplantation in a paediatric ulcerative colitis population: PediFETCh trial
por: Pai, Nikhil, et al.
Publicado: (2017)

Rationale and design of a multicentre, 12-week, randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated trial to investigate the efficacy and safety of elobixibat for chronic constipation
por: Tanaka, Kosuke, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_d65efs0a2ccurtp1ig6bko58n3